SRS Predictive outcomes in meningioma treatment

• Research type

  Research Study

• Full title

  Stereotactic radiosurgery in the treatment of cerebral meningioma, what factors predict outcome?

• IRAS ID

  274400

• Contact name

  Lucy McGavin

• Contact email

  lucy.mcgavin@nhs.net

• Sponsor organisation

  University Hospitals Plymouth NHS Trust

• Clinicaltrials.gov Identifier

  n/a, n/a

• Duration of Study in the UK

  1 years, 0 months, 1 days

• Research summary

  PLAIN ENGLISH SUMMARY

  A meningioma is an abnormal growth of the thin layer of tissue surrounding the brain and spinal cord. This study just deals with meningiomas affecting the brain.
  Meningiomas are the most common brain tumour, and although they tend to grow slowly and do not usually spread, they can cause symptoms, usually by pressing on the brain and other structures such as blood vessels.
  The usual treatment for a meningioma is for a neurosurgeon to operate and remove it. Sometimes, this is the only treatment needed. f this is not possible because of the meningioma is located (deep in the skull or close to vital structures), or if a meningioma has re-grown after surgery, an alternative treatment known as SRS (stereotactic radiosurgery) can be used.
  SRS is a form of specialised radiotherapy which delivers a high-dose radiation into the centre of the meningioma, with the aim of killing the tumour cells and/or stopping them growing. There are also some side-effects after SRS treatment, such as oedema (swelling) in the brain around the treated tumour. Generally, this oedema (swelling) settles with time.

  Little is known about how the general state of the brain in general affects SRS treatment of meningiomas, especially complications of SRS.
  
  This study aims to answer unknown questions about how meningiomas of different shapes and sizes, in different locations respond to treatment with SRS, and how the general state of the brain (previous strokes, other damage, overall size of the brain) affects response to SRS in order to guide oncologists delivering the treatment, so that they can explain the likelihood of treatment success better to patients, and aid them to make a more informed choice.
  

• REC name

  South West - Frenchay Research Ethics Committee

• REC reference

  20/SW/0131

• Date of REC Opinion

  1 Feb 2021

• REC opinion

  Further Information Favourable Opinion